Jeil Pharm (002620) — Cash Flow Reinvestment Rate

Latest as of March 2026: 8.93x

Jeil Pharm (002620) has a Cash Flow Reinvestment Rate of 8.93x as of March 2026, reinvesting ₩3.99 Billion (capex ₩1.72 Billion plus investments ₩-2.27 Billion) from operating cash flow of ₩447.08 Million. Check earnings quality score of Jeil Pharm to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

8.93x
(Capex + Investments) / Operating CF

Total Reinvested

₩3.99 Billion
Capex + Investments

Operating Cash Flow

₩447.08 Million
KRW

Capital Expenditures

₩1.72 Billion
KRW

Jeil Pharm Cash Flow Reinvestment Rate (2011–2025)

Historical reinvestment intensity for Jeil Pharm across 8 annual periods. Explore Jeil Pharm (002620) investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Jeil Pharm (2011–2025)

Year-by-year capital reinvestment analysis for Jeil Pharm. For live market cap and broader valuation context, see market value of Jeil Pharm.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2025 41.01x ₩16.00 Billion ₩390.26 Million ₩9.33 Billion ▲ +1111.8%
2024 3.38x ₩15.37 Billion ₩4.54 Billion ₩6.86 Billion ▲ +32.6%
2021 2.55x ₩34.19 Billion ₩13.40 Billion ₩23.69 Billion ▲ +44.8%
2019 1.76x ₩44.43 Billion ₩25.22 Billion ₩37.69 Billion ▲ +107.5%
2017 0.85x ₩5.03 Billion ₩5.92 Billion ₩2.94 Billion ▼ -84.0%
2016 5.30x ₩60.20 Billion ₩11.36 Billion ₩30.33 Billion ▲ +87.4%
2015 2.83x ₩7.76 Billion ₩2.74 Billion ₩6.74 Billion ▲ +159.0%
2011 1.09x ₩25.82 Billion ₩23.63 Billion ₩22.40 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow